Five things for pharma marketers to know: Monday, December 11, 2017

Share this content:


1. An authorized generic version of Pfizer's erectile dysfunction drug Viagra is now on the market.
It is selling at $30 to $35 per pill, compared to $65 per pill for the brand-name drug. Teva Pharmaceutical Industries is also launching a generic version of Viagra today. (Medscape)

2. GlaxoSmithKline is pursuing deals for early-stage cancer and immunology drugs to strengthen its oncology unit, Luke Miels, GSK's new head of pharma, told Reuters. (Reuters)

3. Ionis Pharmaceuticals' experimental Huntington's disease drug IONIS-HTT(Rx) tackled a protein defect for the first time. The early-stage trial results prompted Roche to invoke its licensing option for $45 million. (Reuters)

4. In its newly released 2018 guidelines, the American Diabetes Association recommends that certain type 2 diabetes patients use glucose-lowering agents with cardiovascular benefits (such as Novo Nordisk's Victoza) and mortality-reducing drugs (like Boehringer Ingelheim/Lilly's Jardiance). (Medscape)

5. The FDA accepted Regeneron's supplemental biologics license application for a 12-week dosage of eye drug Eylea for patients with wet age-related macular degeneration. (Healio)

Share this content:
Scroll down to see the next article